Terumo Corporation: From Fever Thermometers to the Operating Room

I. Introduction & Episode Roadmap

Somewhere right now — a cath lab in Bangkok, a cardiac suite in Chicago, an angio room in Munich — a cardiologist is standing at a patient's right wrist, feeling for the radial artery. A needle goes in. A thin sheath follows. And then the physician threads a wire, roughly the diameter of a guitar string, up the arm, around the shoulder, through the aortic arch, and into a coronary artery narrowed by decades of plaque.

That wire has to be stiff enough to push and floppy enough not to perforate. It has to slide through a wet, pulsating, branching vessel without catching. The physician cannot see it directly; they read it through fluoroscopy and, more importantly, through their fingertips — a tactile conversation between hand and hardware. The whole procedure is built on the assumption that the wire behaves the same way today as it did in the last hundred cases.

There is a good chance that wire was made by テルモ Terumo, a Tokyo company that started life making fever thermometers because Japan could not import them from Germany.

Most patients have never heard the name. Most Western generalist investors have never modelled it. And yet in the fiscal year that ended March 31, 2026, Terumo reported revenue of ¥1,131.9 billion — roughly $7.5 billion at the ¥151-to-the-dollar rate the company actually realised — up 9.2% reported and 8.6% excluding currency effects.¹ Operating profit reached ¥176.3 billion, net profit ¥135.9 billion, and earnings per share ¥92.14.¹ That was a sixth consecutive year of record revenue and record profit, and the company employs more than 30,000 people selling into more than 160 countries.¹² As of August 10, 2026, the shares traded around ¥2,575 for a market capitalisation near ¥3.8 trillion, at roughly 23 times trailing earnings.³

Here is the tension that makes Terumo interesting rather than merely large.

For a hundred years, this company got rich doing something deeply unglamorous: making enormous quantities of small, precise, single-use plastic-and-metal objects that hospitals buy every day and never think about. Syringes. Catheters. Guidewires. Blood bags. It is a business model closer to a specialty industrial than to a device "innovator" — win on manufacturing consistency, win on cost, win on being the thing the physician's hands already know.

And now, under a chief executive barely two years into the job, Terumo has spent the equivalent of roughly a quarter of a trillion yen buying its way into two categories it had never operated in: keeping donated human livers alive outside the body, and manufacturing other companies' injectable drugs. In the twelve months to March 2026 the company paid out ¥248.3 billion in cash for acquisitions, borrowed ¥239.8 billion to help fund it, and watched its equity ratio fall from 74.8% to 68.5% and its goodwill and intangibles balloon from ¥545.2 billion to ¥803.4 billion.¹ That is not a bolt-on. That is a company changing its risk profile.

This story runs in that order. A brief origin — because the founding instinct still explains the business model. Then the acquisition sequence that turned a Japan-centric consumables maker into a three-pillar global medtech. Then the deepest treatment of all: the cardiac and vascular franchise that generates six out of every ten yen of segment profit, and the specific, testable question of whether its advantage is real or merely incumbent. Then the ballast business and its contract-manufacturing gamble, the quiet blood-technology compounder, and the OrganOx deal that is either the smartest thing Terumo has done in a decade or its most expensive act of category tourism.

Then the parts that decide whether any of it accrues to owners: the capital allocation record, the leadership transition, the currency and China exposures, and the case for and against.

Start with the thermometer.

↑ Back to Top

II. Origins: A Thermometer Company Born of Wartime Necessity (1921–1970s)

In 1921 Japan had a shortage of a very ordinary thing: clinical thermometers. The First World War had severed the supply of German-made instruments on which Japanese hospitals had come to depend, and a wartime import blockade turned a routine bedside tool into a scarce good. Physicians could not measure fevers reliably. In an era before antibiotics, when the temperature curve was often the only quantitative signal a doctor had, that was not a procurement inconvenience. It was a clinical blindfold.

A group of physicians decided to fix it themselves. Chief among them was 北里柴三郎 Kitasato Shibasaburo, the bacteriologist who had trained under Robert Koch in Berlin, co-discovered the tetanus antitoxin, and by then presided over the Japan Medical Association. In September 1921, Kitasato and his colleagues incorporated 赤線検温器 Sekisen Ken-onki — literally the "Red-Line Thermometer Company" — in Tokyo, and the first Japanese-made clinical thermometers offered for commercial sale shipped shortly after.²⁴

It is worth pausing on what kind of founding this was. Terumo was not launched by an entrepreneur chasing a market. It was launched by customers who could not buy what they needed and decided to manufacture it. The founding constituency was the medical profession, and the founding problem was supply reliability of a commodity that had to be exactly right every single time.

That is the DNA. Not invention for its own sake — dependability at volume.

The company spent the next five decades widening that idea rather than abandoning it. Thermometers gave way to disposable hypodermic syringes, then to intravenous solution sets, blood bags, and the whole plumbing of the hospital ward. Each of these products shared a profile: high unit volume, low unit price, mission-critical failure modes, and a manufacturing challenge — sterility, dimensional tolerance, material purity — that was much harder than the finished object looked. Japan's first successful practical application of ethylene oxide gas sterilisation belonged to Terumo, and the plastic-moulding and aseptic-filling know-how the company accumulated in those years is the same know-how it markets to pharmaceutical companies today.⁵

In 1974 the company took the name Terumo — an anglicised nod to "thermo," a tip of the hat to the thermometer that started it and a signal that the product line had long since outgrown it.²

Two things carried forward from this period into the modern investment case, and both are more important than they sound.

The first is a preference for recurring consumables over capital equipment. A hospital buys an imaging system once a decade; it buys syringes and guidewires by the pallet, forever. Terumo's revenue base is therefore structurally less lumpy than that of an equipment vendor, and its customer relationship is refreshed daily rather than at tender intervals. That is why the business compounds quietly rather than spectacularly.

The second is a specific kind of engineering conservatism. When your product is inserted into a human body and the physician cannot see it, the highest-value attribute is not novelty. It is that this one feels identical to the last one. Terumo's chief executive would articulate this precisely in November 2025, describing "high-quality products with uniformity and minimal variation" as the thing that gives physicians "the confidence that using Terumo products will deliver a familiar feel in daily clinical practice."[^6] A century earlier, the pitch to Japanese doctors was essentially the same: this thermometer will read correctly.

What the thermometer era did not give Terumo was scale outside Japan, or a position in the operating room rather than the ward. Getting both required a different instrument — and, eventually, a chequebook.

↑ Back to Top

III. Building Three Pillars Through M&A (1980s–2011)

The single most consequential product in Terumo's history was not acquired. It was launched in 1985, and it looked like nothing at all: a thin wire with a slippery coating.⁶

The RADIFOCUS guidewire solved a problem that had been quietly limiting what interventional medicine could do. A bare metal wire dragging along the inside of a blood vessel generates friction, and friction in a vessel means resistance, trauma, and a physician fighting the device instead of navigating the anatomy. Terumo's answer was a nitinol core covered in polyurethane and coated in a hydrophilic polymer — a surface that, on contact with blood, becomes genuinely slippery.⁷ The analogy that works: it is the difference between pushing a dry rope through a narrow pipe and pushing a wet one.

Two consequences followed, one obvious and one strategic.

The obvious one is that lubricity let physicians reach lesions they previously could not. The strategic one is that it made access through the wrist practical. Before hydrophilic wires, coronary intervention overwhelmingly went in through the femoral artery in the groin — a large vessel, easy to enter, but one that requires the patient to lie flat for hours afterwards while a bleed risk is managed. The radial artery at the wrist is smaller, more tortuous, and harder to navigate, but it can be compressed with a simple band, which means the patient sits up, walks, and frequently goes home the same day. Radial access is better for the patient and cheaper for the hospital; it was simply, for a long time, technically harder.

Terumo did not merely sell wires into that shift. It underwrote it — building a full radial product line, and running physician training programmes to teach a technique that happened to run on Terumo hardware.[^6] Four decades later the company still markets the wire as the reference standard of the category.⁷ By 2024, on the company's own tracking, radial access accounted for 79% of coronary procedures, comfortably ahead of the 75%-plus penetration target management had set for 2026, and up from 68% in 2021.⁵⁸

This is a genuinely unusual competitive asset, and it deserves to be named precisely. Terumo did not win a market; it helped define a clinical practice and then supplied it. Practices, unlike products, are sticky — they are embedded in hospital protocols, fellowship training, and physician muscle memory.

What Terumo could not manufacture organically was breadth. Interventional medicine was fragmenting into specialties — neurovascular, aortic, structural heart — each with its own physicians, its own evidence base, and its own incumbent. So the company started buying, and the pattern of those purchases is the best available guide to how it thinks.

In 2002 it bought Vascutek, a Scottish vascular graft maker, seeding what became the aortic business. In 2006 it acquired MicroVention, a California company founded in 1997 that made coils for treating brain aneurysms — Terumo's entry into neurovascular intervention.⁹ The purchase price was not disclosed at the time. That deal is worth remembering for two separate reasons: it eventually became the company's fastest-growing franchise, and the executive who ran the acquisition process would, eighteen years later, become chief executive.¹⁰

MicroVention set the template Terumo has repeated ever since: buy a technically credible platform in an adjacent interventional specialty, leave it operating under its own brand and leadership, feed it capital, and let it compound. Terumo added Sequent Medical in 2016 for $280 million at closing plus up to $100 million in milestone payments, acquiring the WEB intrasaccular device — a small mesh basket deployed inside an aneurysm rather than packed into it.¹¹ It took until 2024 to fold the whole thing under a single identity, Terumo Neuro.⁹ Eighteen years of patient ownership before rebranding is either admirable restraint or slow integration, depending on temperament; the results argue for restraint. Terumo Neuro generated roughly $710 million of sales in the fiscal year ended March 2025, with therapeutic devices about 70% of the total, and has grown at a double-digit compound rate since the acquisition.⁹

Then came the deal that changed the company's shape.

In March 2011, Terumo agreed to buy CaridianBCT — the blood-technology arm of Sweden's Gambro — for $2.63 billion including debt, becoming the world's largest maker of blood-transfusion equipment overnight.¹²¹³ It was, at the time, an extraordinary sum for a Japanese medical device company to spend abroad. Bloomberg reported the price at roughly 15 times CaridianBCT's 2010 EBITDA, funded with cash and bank loans.¹³ Combined with Terumo's existing transfusion business, it created Terumo BCT and instantly manufactured a third pillar where there had been a niche.

Fifteen times EBITDA for a mid-sized equipment business in 2011 was not a bargain. It was a price that assumed the acquirer could grow the asset materially and hold its margin — and, crucially, a price that would look either shrewd or foolish only after a decade. Hold that thought. It returns twice: once when the blood business is examined on its merits, and once when the same question is asked of a deal signed in 2025.

By the early 2010s, then, the architecture was set: three internal "companies," each with its own president, its own product logic, and its own competitive set. Cardiac and Vascular. Medical Care Solutions. Blood and Cell Technologies. That structure still governs how Terumo reports, plans, and pays its executives.

The largest of the three is where the money is made.

↑ Back to Top

IV. The Core Engine: Cardiac and Vascular — Industry Structure and How Terumo Wins

Walk into an American hospital's cardiac catheterisation lab and count the logos. The imaging system might be Philips or Siemens. The drug-eluting stent going into the artery is probably Abbott or Boston Scientific or Medtronic. The replacement heart valve, if there is one, is most likely Edwards. These are the headline products, the ones with the pivotal trials and the multi-billion-dollar franchises.

Now look at the table beside the physician. The sheath in the wrist. The guidewire. The support catheter. The microcatheter threading the guidewire deeper. The balloon. Those are consumed by the dozen, cost a fraction of the implant, and are chosen almost entirely by physician preference rather than hospital committee.

That table is Terumo's kingdom, and it is a bigger kingdom than the logo count suggests. The Cardiac and Vascular Company generated ¥676.4 billion of revenue in the year to March 2026 — about 60% of group sales — and ¥164.0 billion of segment profit, a 24% margin that made it comfortably the group's profit engine.¹ It contains four businesses: Terumo Interventional Systems (coronary and peripheral access, therapeutic devices, and imaging), Terumo Neuro, Terumo Aortic, and Terumo Cardiovascular, which makes the oxygenators and pumps that keep blood circulating during open-heart surgery.

The industry structure, honestly described

This is an oligopoly, but not a comfortable one, and the forces acting on it are worth setting out plainly.

Barriers to entry are high and mostly regulatory and evidential. Getting a device approved requires clinical data; getting it used requires more clinical data plus physicians willing to change habit. That protects everyone already inside — including Terumo — and it is the main reason technology disruption risk in this industry is genuinely lower than in, say, software. Nobody builds a coronary guidewire company in a garage.

Buyer power, however, is real and rising. Hospitals consolidate into systems with professional procurement functions, and in several major markets the buyer is not a hospital at all but a government running a national tender. That is a structural squeeze on price that does not reverse.

Supplier power is moderate. The raw inputs — polymers, nitinol, tungsten — are specialty but not scarce, and Terumo's scale gives it leverage.

Rivalry is intense but fought on axes other than headline price: clinical outcomes data, physician training and relationships, and total procedural cost. And the threat of substitution runs mostly the other way — minimally invasive catheter procedures keep taking share from open surgery, which is a tailwind for everyone in the category.

Within that structure, Terumo occupies a specific and somewhat unusual position: it is not the leader in the most profitable product pools, and it is dominant in the least glamorous ones.

What Terumo actually sells, and why it is more defensible than it looks

On the November 2025 earnings call, chief executive Hikaru Samejima laid out the interventional business with more candour than these presentations usually contain. Access products — sheaths, wires, the hardware that gets you into and along the vessel — account for roughly half of divisional revenue. Add what Terumo calls Therapeutic Lesion Access (the guidewires and microcatheters that deliver someone's stent or coil to the target) and the two together are more than 80% of the division.[^6]

Samejima described this concentration not as a limitation but as the differentiator: "this is a key differentiator from our competitors." His argument was that Terumo has taken products the market treats as commodities and made them not-commodities, through three mechanisms.

The first is process capability. Hydrophilic coating chemistry and precision extrusion are not patent-protected in any durable way — they are accumulated manufacturing know-how, refined over decades, that is genuinely hard to replicate at scale with low defect rates. In Hamilton Helmer's taxonomy this is process power, the least glamorous and most underrated of the seven, and it is arguably Terumo's single strongest source of advantage.

The second is scale in a category where scale is unusual. Most competitors treat access devices as an accessory line supporting a flagship implant. Terumo treats them as the flagship, which lets it run large-scale, multi-product manufacturing that, in management's framing, "creates a barrier to entry that competitors cannot easily overcome."[^6] That is a self-serving statement, but it is testable, and the test — can Terumo hold high-single-digit volume growth in access without discounting? — has so far been passed. In the third quarter of the year to March 2026, the division grew 8% in local currency with, in the CFO's words, volume contributing more than pricing.¹⁴

The third is switching cost, and it is the subtlest. Physician preference in access devices is a tactile habit. A cardiologist who has done 2,000 cases with a particular wire has calibrated their hands to it. Switching means relearning feel under time pressure with a patient on the table. That is not a contract lock-in; it is something closer to a musician's attachment to a specific instrument — and it is why these "commodity" products carry the margins they do.

Add the fourth pillar, imaging, which is where Terumo is making its most interesting technical bet.

The imaging bet, explained simply

Interventional cardiologists have two ways to see inside an artery from the inside. IVUS uses ultrasound: it penetrates deep, shows the whole vessel wall and its overall condition, but blurs fine detail. OCT uses near-infrared light: gorgeous resolution for stent struts and calcium, but shallow penetration and it requires flushing blood out of the vessel with contrast dye to see anything. Think of it as a wide-angle lens versus a macro lens. Each answers questions the other cannot.

In practice, on cost grounds, a physician usually gets one. Terumo's Dual Sensor System puts both sensors on a single catheter, producing both images simultaneously.[^6] The clinical pitch is that the choice disappears; the commercial pitch is that a catheter doing two jobs can be priced above a catheter doing one.

The market timing argument is credible. Imaging-guided coronary intervention received the highest recommendation level — Class I, Level of Evidence A — from major medical societies, which in practice means guidelines now tell physicians to use it.[^6] Management projects imaging penetration in US coronary intervention rising to 56% by 2031 and the global imaging market reaching $1.3 billion by then, and expects Terumo's imaging revenue to more than triple over that period.[^6]

The reason to take this more seriously than the average product roadmap slide is Japan. Imaging is used in over 95% of Japanese coronary procedures — the highest penetration anywhere — and Terumo holds more than half of that market.[^6] The company is not entering imaging; it is exporting a position it already dominates in the world's most imaging-intensive market into a US market only now adopting the practice. That is a real, evidenced starting advantage.

It is also, honestly, an unproven one commercially. Terumo enters the US imaging market as a challenger against entrenched systems, needs to accumulate American clinical evidence for a device with no direct comparator, and is asking for a price premium. Management said as much: a "phased approach to market introduction," building "a loyal customer base."[^6] Investors should treat imaging as optionality with an unusually good pedigree, not as a booked growth driver.

Where the evidence is thinner

Now the uncomfortable part, and it is the crux of the Terumo bear case.

The highest-value pools in cardiovascular medicine are the implants — transcatheter aortic valves, drug-eluting stents — and Terumo does not lead them. Edwards Lifesciences built structural heart; Abbott, Boston Scientific and Medtronic dominate coronary stents in the United States. These are categories with better unit economics, more clinical mystique, and larger addressable spend than access devices. Terumo competes in them; it is not the reference brand in them.

Management is not hiding from this. Samejima flagged that the coronary intervention market is maturing and that the company is "looking ahead to expanding into therapeutic product areas, including strengthening our pipeline through M&A."[^6] That is a candid acknowledgement that the therapeutic gap will be closed with a chequebook or not at all — which routes straight back to the capital allocation question.

There is also evidence that Terumo's therapeutic ambitions have already cost money without delivering. Over the two most recent fiscal years the company terminated a large-diameter haemostatic device programme, ended a European interventional business, closed a European plant, terminated two separate development projects in the Terumo Aortic and Terumo Cardiovascular divisions, and walked away from an exclusive distribution agreement in the Americas — recognising ¥22.5 billion of impairments in the year to March 2025 and a further ¥11.4 billion in the year to March 2026, the large majority in the Cardiac and Vascular Company.¹¹⁵

Read charitably, that is a company pruning aggressively before the end of a strategic plan. Read sceptically, it is a company that has repeatedly written off its attempts to move up the value chain from access devices into therapeutics. Both readings are defensible on the evidence, and an investor should hold them simultaneously.

The honest summary of this segment: Terumo's competitive position is strongest exactly where the industry assumes there is no competitive position, and weakest where the profit pools are deepest. That is a durable but capped franchise — which is precisely why the other three segments matter more than their revenue share suggests.

↑ Back to Top

V. Medical Care Solutions: The Ballast Business — and a New Growth Angle in CDMO

There is a building in Leverkusen, Germany, about twenty kilometres north of Cologne, that has now been sold twice in five years. Bayer built it. 药明生物 WuXi Biologics bought it in 2020, in the middle of a pandemic-driven scramble for injectable manufacturing capacity. And on September 30, 2025, Terumo bought it — its first drug-product manufacturing site outside Japan, acquired for ¥27.1 billion.¹¹⁶

To understand why a Japanese syringe company bought a German fill-finish plant, start with the segment it sits in.

Medical Care Solutions is the least exciting thing Terumo owns and, for most of the company's history, the most important. It makes the hospital's consumable infrastructure: syringes, infusion sets and smart pumps, intravenous and peritoneal dialysis solutions, pain management products. It also houses the consumer-facing devices — blood glucose meters, blood pressure monitors, thermometers — a mature, heavily Japan-weighted business that is not a growth driver and does not pretend to be.

The numbers describe a utility. Revenue of ¥216.1 billion in the year to March 2026 grew just 2.3% reported and 1.9% excluding currency, with Japanese sales — 70% of the segment — essentially flat at 0.4% growth.¹ Segment profit of ¥21.6 billion represented a 10% margin, less than half the Cardiac and Vascular level and short of the 15% target management set for the segment under its five-year plan.¹⁵

So why does it earn a substantial section? Two reasons, one defensive and one speculative.

The defensive reason is that this segment is the shock absorber. Terumo entered the plan period with Medical Care Solutions as its most damaged business — inflation in raw materials, energy and transport hit a low-margin, Japan-heavy, regulated-price business harder than anything else in the group. Samejima, who ran the segment before becoming chief executive, described the recovery in May 2025 as "a V-shaped recovery in profitability" achieved through pricing measures and cost reduction.¹⁵ The three-year revenue compound growth to that point was 4%, or 2% at constant currency — the weakest in the group, and a fair reminder that "ballast" is a polite word for "slow."⁵

The speculative reason is the one that could matter to the next decade.

Deviceuticals, in plain language

Terumo has spent fifty-plus years doing two things that are usually done by different companies: manufacturing precision plastic devices, and handling pharmaceutical products — it launched its first drug product in 1969.¹⁵ That combination produces a specific capability: designing the container and the delivery mechanism for an injectable drug, and then filling it.

This matters more now than it did twenty years ago because of what drugs have become. A traditional small-molecule pill needs no device. A modern biologic — a monoclonal antibody, or one of the injectable metabolic drugs that has reshaped pharmaceutical demand — is a large, fragile molecule that must be injected, often repeatedly, often by the patient at home. The device is no longer packaging. It is part of the therapy.

Terumo's argument, which Samejima has made consistently, is that the contract manufacturing industry is fragmented by process step: pharmaceutical companies must sign separate contracts for drug substance, for device, for filling, and then manage the seams between them. Terumo offers to take the whole span — engaging early in drug development, designing a delivery device suited to the specific molecule, and filling it.¹⁵⁵ The company brands the concept "Deviceuticals" and its flagship demonstration is an on-body injector: a patch-like unit that automatically delivers a drug subcutaneously at home over an extended period, built from Terumo's polymer syringe, its pump engineering, and its needle technology.⁵

Management's market framing sizes formulation and filling at roughly $12 billion growing at an 11% compound rate, administration device manufacture at $1.9 billion growing 7%, and needle-bundled-with-drug at $300 million growing 6% — figures Terumo attributes to its own research and which should be read as directional, not audited.⁵ Terumo formally launched the contract manufacturing business in fiscal 2017, has expanded capacity to roughly 2.5 times fiscal 2015 levels, completed a new building at its Kofu plant in September 2025, and targets more than four times the fiscal 2015 base by 2030.¹⁵⁵

A concrete customer proof point exists: Terumo manufactures an autoinjector for Eisai's Alzheimer's therapy LEQEMBI, with the revenue booked in Japan under the terms of that contract.[^6]

Why Leverkusen, and what it has cost so far

The strategic logic for buying rather than building was time and geography. Samejima said Terumo had been approaching European pharmaceutical companies for about two years, received positive responses, and repeatedly failed to convert them into contracts because it had no European production site.¹⁵ Buying an operating plant with trained staff compressed years of construction and hiring into a single transaction.

The execution reality has been less tidy, and management has been unusually direct about it — which is to its credit.

The plant contributed a ¥1.6 billion loss in its first consolidated quarter.¹⁴ Running costs were guided at roughly $30 million per half-year, and the CFO stated flatly that these "we do not project will be going down anytime soon."[^6] Most importantly, when an analyst pressed on timing, Jin Hagimoto said the profit contribution was "not within the GS26 period" — meaning not by March 2027 — and would arrive "in the midterm of the next midterm strategy period."[^6] Terumo is deliberately staging capital expenditure on production lines "step-by-step as the certainty of customer contracts increases."¹⁴

Translate that: Terumo bought a factory before it had customers for it, is burning roughly $60 million a year running it, has signed non-disclosure agreements but no announced contracts, and does not expect it to make money for several years.

That is not necessarily a bad decision — capacity-before-contract is how the contract manufacturing industry works, and Terumo's existing Japanese business has grown ahead of the market since 2017.⁵ But it is a decision that converts a stable, cash-generative segment into one carrying a loss-making growth option. The falsifiable test is simple and will arrive on a specific timeline: announced European pharmaceutical contracts within the next two years, or the thesis weakens materially. Until then, contract manufacturing is a call option that Terumo is paying real premium to hold.

The company's third pillar poses a similar question with fifteen more years of evidence attached.

↑ Back to Top

VI. Blood and Cell Technologies: The Quiet Cash Compounder

In a plasma collection centre in Texas, a donor sits in a reclining chair with a needle in one arm. Blood flows out, a centrifuge spins off the straw-coloured plasma, and the red cells return to the donor's vein. The cycle repeats for roughly forty-five minutes. The plasma goes on to be fractionated into immunoglobulins and clotting factors — biological medicines that cannot be synthesised and for which demand has grown relentlessly.

The machine doing the spinning is capital equipment. The disposable kit — the tubing, the bowl, the filters, everything that touches blood and is thrown away afterwards — is consumed once per donor, per session, forever.

That is the entire economic architecture of Terumo's Blood and Cell Technologies segment, and it is the cleanest razor-and-blades model in the company. Place a device; sell disposables against it for a decade.

In the year to March 2026, the segment produced ¥231.0 billion of revenue, up 15.4% and 15.2% excluding currency — by a wide margin the group's fastest-growing pillar — with segment profit of ¥33.6 billion.¹ Growth was driven overwhelmingly by plasma, and specifically by Rika, Terumo BCT's automated plasma collection system.

The Rika story, and why it cuts both ways

Rika's commercial history is a case study in how a razor-and-blades model can succeed and disappoint at the same time.

The device was slowed out of the gate by the pandemic, which management acknowledged had pushed back the rollout and was a principal reason the segment's margin lagged its 20% target.¹⁵ Once deployed, it moved fast: by May 2025 Rika had been installed in roughly 90% of the plasma collection centres of its anchor customer base, and installation at existing customers was completed during the first quarter of the year to March 2026.[^6]¹⁵ Terumo also signed an exclusive agreement with Join Parachute beyond its foundational relationship with CSL.¹⁵

Then came the wrinkle, and it is a genuinely interesting one. Rika turned out to be more efficient at collecting plasma than expected. Because it extracts more plasma per session, centres need fewer sessions — and therefore fewer disposable kits — to hit the same plasma volume. The CFO described this with something close to rueful humour on the November 2025 call: plasma demand is rising, "but our disposable sets compared to expectations, the demand is going slightly down, ironically."[^6] Terumo cut production in the second half of the year.

This is a structural feature of the model that investors should internalise rather than treat as a one-off. In a razor-and-blades business, product improvement can cannibalise the blade. Terumo managed the immediate financial impact well — by the February 2026 call, management reported the production adjustment had hurt less than feared because of manufacturing efficiency gains, and the segment's margin improved anyway.¹⁴ But the episode establishes that consumable volumes here are not a simple function of end-market plasma demand.

A second concentration risk surfaced on the same February call, when a Macquarie analyst asked directly about upheaval at CSL, Terumo's largest plasma customer. Management declined to comment on the customer's situation but conceded there "may be some discussions about the volume in the future."¹⁴ For a segment whose growth engine is one product sold heavily into one customer category dominated by a handful of global plasma collectors, that is not a trivial exposure. It is the kind of qualitative concentration risk that does not appear in a segment table.

The competitive set, and the adjacency

Terumo BCT's closest global peer is Haemonetics, whose regulatory filings name Terumo BCT, Fresenius and Abbott as significant competitors and identify Rika directly as the rival to its own plasma platform — a rivalry made concrete when CSL moved to Rika.¹⁷ On the plasma-collection and fractionation side, Grifols and Fresenius Kabi are the other names that matter.

Beyond blood, the segment holds what may be its most interesting long-term asset: the cell collection technology used to harvest a patient's own immune cells for cell and gene therapies. Management has reported growing revenue from cell collection tied to expanding cell and gene therapy demand, particularly in North America.[^6]¹⁴ This is genuine adjacency — the same apheresis engineering, applied to a biotech manufacturing workflow with far higher value per procedure. It is small today and Terumo does not break it out, but it is the segment's optionality, and it is optionality Terumo owns rather than must buy.

CaridianBCT, fifteen years on

So: was $2.63 billion at roughly fifteen times EBITDA the right price in 2011?

The verdict is genuinely mixed, and the mixedness is the useful part.

On the positive side, the deal bought Terumo a global leadership position in a growing, high-barrier category it could not have built organically, and it is now the fastest-growing and second-most-profitable pillar in the group. Blood technology gave Terumo a foothold in cell and gene therapy manufacturing infrastructure that no amount of guidewire expertise would have provided. Strategically, it worked.

On the negative side, the timeline was long and the profitability target has not been reached. Segment margin ran at roughly 14.6% in the year to March 2026 — improving, but still meaningfully below the 20% goal management set for the segment under its plan, with currency weakness and the delayed Rika ramp cited as the reasons.¹⁵ Management noted in May 2025 that excluding exchange rate effects the margin was "quite close to 20%," which is a fair point about optics but does not change the cash outcome for a Japanese-reporting company.¹⁵

The honest scoring: CaridianBCT was a strategically correct acquisition at a full price that required roughly a decade and a half of operational work to justify, and the justification is still incomplete on management's own metric. That is not a disaster. It is also not the record of a company that reliably buys assets cheaply.

Which is exactly the lens to bring to the biggest cheque Terumo has ever written.

↑ Back to Top

VII. The Biggest Bet Yet: OrganOx and Entry into Organ Transplant Technology (2025)

A human liver, once removed from a donor, begins to die. Packed in ice — the standard of care for decades — it survives perhaps six hours, and every hour degrades it. That clock governs everything downstream: how far the organ can travel, whether the surgery happens at two in the morning, and, most consequentially, whether a marginal organ is used at all or discarded because nobody can be certain it will work.

The numbers are brutal. Roughly 37% of potentially transplantable livers from available donors in the United States go unused.¹⁸ More than 8,000 patients worldwide are estimated to die each year waiting for an organ, around 6,000 of them in the US.¹⁸

Now imagine a different approach. Instead of chilling the liver, you keep it warm and alive — pumping oxygenated, temperature-controlled blood through it, exactly as the body would. The organ metabolises. It produces bile. It behaves like a functioning liver, and because it does, you can measure whether it is a functioning liver: circulatory pressure, blood gases, temperature, all read out continuously. Preservation extends to 12 hours under the US label and 24 hours in Europe.¹⁸

That is normothermic machine perfusion, and the technology came out of the University of Oxford, where the core work began in 1997 and was spun out as OrganOx in 2008.¹⁸

The strategic prize is not simply longer preservation. It is that quantitative assessment converts "we cannot be sure, so discard it" into "we can measure it, so transplant it." Every marginal organ that becomes usable is a life. It is also a unit sold.

The deal

Terumo signed on August 23, 2025 and announced on August 24 an agreement to acquire 100% of OrganOx for approximately $1.5 billion on a cash-free, debt-free basis, funded with cash on hand and debt.¹⁸¹⁹ The transaction closed on October 29, 2025 — the largest exit ever recorded for an Oxford University spinout.²⁰ In the fiscal year that followed, the business was designated Terumo Organ Technologies and became the group's fourth reportable segment.¹

Terumo was not a stranger to the company. It had supplied a component of OrganOx's device since 2017, and its corporate venture arm had taken a 0.4% stake in March 2025 — five months before agreeing to buy the rest.¹¹⁸

Interrogating the price

Here the purchase price allocation disclosed in the annual results is far more revealing than the press release, and it deserves careful reading.

Total consideration came to ¥230.6 billion. Against that, Terumo recognised ¥92.6 billion of intangible assets — mainly technology-related and in-process R&D — and ¥138.2 billion of goodwill, none of it tax-deductible.¹ The fair value of all identifiable net assets acquired was ¥96.2 billion.¹

In other words, roughly 60% of the price was goodwill: an accounting statement that Terumo paid for expected future earning power rather than for anything it can point at.

Against reported financials the multiple is steep. OrganOx generated $71 million of revenue in calendar 2024 at a 17% adjusted EBITDA margin — its second profitable year, after -28% in 2022 and 15% in 2023.¹⁸ At $1.5 billion, that is roughly 21 times trailing revenue. Against Samejima's November 2025 statement that calendar 2025 revenue would reach "up to $120 million," approximately 70% growth, the forward multiple compresses to roughly 12 times — still full, but within the range paid for high-growth medtech platforms.[^6]

The bull framing is that this is a razor-and-blades machine in a category with no meaningful installed base yet, growing above 50%, already profitable, with a kidney device in development targeting commercialisation around 2030 and a smaller next-generation liver unit in the pipeline.¹⁸ Terumo has stated an ambition of roughly ¥100 billion of revenue from the business within ten years — more than twelve times its current run rate.[^6]

The bear framing is equally available. This is a single-product, single-organ company. Its market depends on donor supply, which is not under Terumo's control and which management has already had to flag: on the February 2026 call, the company disclosed that third-quarter revenue came in below its own expectation "due to a slowdown in donors."¹⁴ It operates in a clinical field where Terumo has no history, no sales force, and no physician relationships. And it is exposed to policy: an analyst raised a state-level investigation into organ procurement practices in Florida, to which management responded that any impact would be short-term.[^6] That is an assertion, not evidence.

What the first three quarters actually showed

Terumo Organ Technologies contributed ¥8.0 billion of revenue and ¥1.665 billion of segment profit — a 21% margin — over the roughly five months of consolidated ownership in the year to March 2026.¹ Disclosed on a full-year comparable basis through December 2025, the business grew about 50% year-on-year with margin improving from 13% to 21%.¹⁴

Pressed by Macquarie on whether that margin expansion reflected Terumo cost cutting, management gave an answer worth noting for its restraint: no, this was OrganOx's own organic operating leverage, executed on plans made before the acquisition.¹⁴ The business simply has high incremental margins as volume covers fixed cost.

That is a good answer, and also a slightly awkward one. It means the early margin improvement is not evidence that Terumo adds value; it is evidence that Terumo bought a business that was already improving. The synergy case — integrating Terumo's centrifugal pumps, oxygenators, heat exchangers and reservoirs, all of which it already manufactures under the CAPIOX brand and all of which appear inside a perfusion machine — is entirely credible on an engineering level and entirely unproven on a financial one.[^6]

The first quarter of the current fiscal year added a data point in each direction. Revenue of ¥6.2 billion annualises well ahead of the prior run rate; segment margin of about 15% came in below the 21% recorded previously, and Terumo also absorbed ¥2.6 billion of non-recurring expense from the inventory step-up required when acquired stock is revalued to fair value.²¹ Purchase accounting will continue to depress reported profitability: intangible amortisation attributable to the segment ran at ¥1.6 billion in a single quarter.²¹

The verdict available today is deliberately incomplete. The asset is growing fast, is genuinely differentiated, and addresses an unambiguous clinical need. The price embeds an assumption of sustained rapid growth into a category that barely exists yet, and the operational integration has not begun in earnest. It is the same shape of bet as CaridianBCT — pay a full price for category leadership and earn it back over a decade — with the difference that CaridianBCT was a mature business bought at fifteen times cash earnings, while OrganOx is an emerging one bought at roughly twelve times forward revenue.

Whether the pattern is discipline or drift depends on what else Terumo has been doing with its money.

↑ Back to Top

VIII. The Capital Allocation Scorecard

In December 2021, on the company's hundredth anniversary, Terumo published a five-year growth strategy called GS26 and put three numbers on the table.

Revenue growth: a five-year compound average in the high single digits, aiming at ¥1 trillion of revenue. Operating profit margin: 20% or better within five years. Return on invested capital: 10% or better, while maintaining return on equity above 10%. Two footnotes qualified the exercise: the profitability and ROIC targets excluded the impact of any new M&A, and the revenue figure assumed ¥107 to the dollar.⁴

Four and a half years later, in May 2026, Samejima put up a slide declaring all three targets achieved: a five-year revenue compound growth rate of 12%, a 20% operating profit margin in the final year, and 10% ROIC — with a footnote reading "excluding new M&A executed in FY25."⁹

This is where a neutral reader has to slow down, because the gap between that slide and the audited accounts is instructive.

Reading the scorecard critically

On revenue, the 12% headline is currency-inflated. The same slide disclosed the constant-currency figure in parentheses: 7%.⁹ Against a target described as "high single-digit," 7% is at or fractionally below the bottom of the stated range. Terumo hit its revenue ambition in yen because the yen collapsed, and management deserves credit for disclosing the constant-currency number rather than burying it — but the underlying growth was good, not exceptional.

On margin, the reported operating profit margin in the year to March 2026 was 15.6%, and the adjusted operating margin — which strips out acquisition-related intangible amortisation and non-recurring items — was 19.4%.¹ The "20%" on the slide is therefore an adjusted figure further adjusted to exclude the two acquisitions completed during the year. The exclusion was pre-announced in 2021, so it is not a goalpost moved after the fact. But it means the group's actual, GAAP-equivalent operating margin sits more than four percentage points below the number in the headline.

On capital efficiency, reported return on equity was 9.2% in the year to March 2026 and 8.7% the year before — both below the 10% the plan said Terumo would maintain.¹ The internal bonus scorecard for the earlier year is even more revealing: management set itself a ROIC target of 7.6% and delivered 7.5%, and an ROE target of 8.9% against 8.7% delivered.²² Annual incentive targets were being set several points below the five-year public commitment. That is a legitimate thing for an activist to raise.

None of this means the plan failed. Terumo grew revenue by roughly 84% over five years, more than doubled net profit, and improved adjusted margin materially from a 2022 trough — a genuinely strong operating record. It means the victory lap is presented on management's preferred basis, and the reader should do the translation.

The shareholder return promise, and what actually happened

Terumo's stated distribution policy is a stable, rising dividend supplemented by buybacks, targeting a total shareholder return ratio of 50%, weighed against growth investment and financial soundness.¹²³

The dividend has done its part: ¥26 per share for the year to March 2025, ¥30 for the year to March 2026, and ¥36 guided for the current year — a 38% increase across two years.¹ The payout ratio, however, has sat at 32.9%, 32.6% and a guided 32.1% respectively.¹ Consistent, deliberate, and nowhere near 50%.

The gap was supposed to be closed by repurchases. In the year to March 2026, treasury shares actually declined slightly, from 5,608,213 to 5,476,639 — the arithmetic signature of no buyback at all.¹ The reason is not mysterious: the company spent ¥248.3 billion acquiring businesses and ¥85.2 billion on property, plant and equipment, and financed it with ¥239.8 billion of new borrowing.¹

That is the three-stage capital priority working exactly as designed — growth investment first, dividend second, buyback last — and it is intellectually consistent. It is also, from a shareholder's seat, a year in which a 50% total payout target produced a 33% payout.

Management knows the market noticed. Asked directly about buybacks in February 2026, an executive declined to comment on repurchases but volunteered something more candid: "we are not happy with the stock price of today," adding that share buybacks were "a big topic within our top management meeting" and that the company needed to do "a good job communicating with the people in the marketplace."¹⁴ That is an unusually human answer from a Japanese blue chip, and it signals that the payout question is live rather than settled.

The M&A record, scored

Line the deals up and a pattern emerges that is neither pure discipline nor pure drift.

MicroVention in 2006 was the model outcome: a modest platform purchase in an adjacent specialty, held patiently, compounded at double digits for nearly two decades into a $710 million franchise.⁹ Sequent Medical in 2016 was a well-structured bolt-on with $100 million of the consideration deferred into milestones.¹¹ CaridianBCT was strategically right at a full price with a very long payback.

Quirem Medical is the cautionary tale, and Terumo's handling of it is genuinely creditable. In July 2020 the company acquired the Dutch maker of holmium-based radioactive microspheres for liver tumours, paying $20 million upfront plus up to $25 million in milestones to 2030 — a small, well-structured bet on interventional oncology.²⁴ Five years later, on June 27, 2025, Terumo initiated liquidation proceedings, citing regulatory barriers to expanding outside Europe and intensifying competition, and ceased sales of the beads while keeping interventional oncology as a strategic priority through other product lines.²⁵ The write-offs show up in the accounts: the termination of a business in the European interventional division carried a ¥5.3 billion impairment, of which ¥3.1 billion was goodwill.¹

A small bet, sized so failure was affordable, killed decisively when the thesis broke. That is exactly how bolt-on M&A is supposed to work, and it is more informative about management quality than any of the successes.

The concern is scale drift. The Quirem discipline was easy because $20 million is easy. OrganOx is seventy-five times larger, and it was announced alongside a German factory purchase in the same fiscal year, immediately after a plan period in which management repeatedly emphasised portfolio pruning and profitability. A sceptical investor would note that Terumo promised discipline, spent five years demonstrating it on small assets, and then wrote the largest cheque in its history into a category it had never operated in.

The balance sheet still absorbs it — equity ratio of 68.5%, interest-bearing debt at 1.9 times operating cash flow, interest coverage of 83.7 times — but all three metrics moved meaningfully in the wrong direction in a single year.¹ Terumo has since termed out the funding sensibly, issuing $500 million of five-year dollar notes on April 28, 2026 at a 4.48% coupon swapped down to an effective 2.37%, and ¥40 billion of two-year domestic bonds on July 24, 2026 at 1.716%.¹²¹ Cheap financing, competently hedged, is one thing the company has plainly done well.

One further governance note belongs here. Terumo's share register remains heavily intermediated through Japanese trust banks — The Master Trust Bank of Japan held 22.32% and Custody Bank of Japan 9.26% as of March 2025 — with Dai-ichi Life at 4.09% and Meiji Yasuda Life at 3.31% among the largest identifiable holders, and foreign ownership above 30%.²⁶ Those insurer stakes are the residue of the Japanese cross-holding system that the Tokyo Stock Exchange's capital-efficiency reforms have been steadily dismantling since 2023. Their gradual unwinding is a sector-wide flow dynamic rather than a Terumo-specific event, and treating it as a company-level catalyst would overstate it.

Capital allocation, in the end, is a personality trait. So it matters who is making the decisions.

↑ Back to Top

IX. Leadership: The Samejima Era

In 2006, a mid-career executive in Terumo's strategic planning department flew to California to work on the acquisition of a small aneurysm-coil company called MicroVention. Eighteen years later, that executive became chief executive of Terumo. Nineteen years later, he stood in front of analysts and defended the largest acquisition in the company's history.

Hikaru Samejima joined Terumo in 2002, in his late thirties — not a lifer who entered from university, but not an outsider either. He came in through strategic planning and immediately worked on deals: Vascutek in Scotland in 2002, MicroVention in 2006.¹⁰ From 2007 he ran the interventional systems division — the guidewire and access business that is the company's economic heart. In 2017 he became president of the Cardiac and Vascular Company. In 2020 he moved to run what became Medical Care Solutions, the ballast business with the worst inflation exposure and the weakest margins, and led its recovery. On April 1, 2024, he became president and chief executive.¹⁰ He holds an economics degree from Keio University and an MBA from Duke's Fuqua School of Business.¹⁰

That résumé matters for two reasons. First, it is dealmaker-then-operator, in that order — a chief executive whose formative professional experience was buying companies, and who then spent seventeen years running what he had bought. Second, it means the OrganOx transaction is not out of character. It is the most characteristic thing he could have done.

His predecessor, Shinjiro Sato, ran Terumo from 2015 to 2024 and authored GS26. The continuity question is answerable from the documents, and the answer is: unusually high.

Sato's May 2023 mid-plan presentation set out the three financial targets in the identical form and with the identical footnotes as the original 2021 announcement — high single-digit revenue growth toward ¥1 trillion, 20%-plus operating margin, 10%-plus ROIC while maintaining 10% ROE, both excluding new M&A, both at ¥107 to the dollar.⁴⁸ Samejima's May 2025 and May 2026 presentations carried the same three targets in the same framing.⁹⁵ Over four and a half years and a chief executive transition, Terumo did not quietly reset a single headline number. In a market where mid-term plans are routinely rebased when they become inconvenient, that is a meaningful data point on target-setting integrity.

Where the record is less clean is annual guidance, and here the story is worth telling properly because it is the best available test of how this management explains a miss.

The year Terumo guided down its own operating profit

Terumo entered the year to March 2026 guiding to ¥240.0 billion of adjusted operating profit. In November 2025 it cut that to ¥221.5 billion — an 8% reduction — while simultaneously raising revenue guidance.[^6]

The composition of the cut is the interesting part, and Hagimoto walked through it with more granularity than the reduction strictly required. Underlying business performance was ¥10 billion better than plan. Tariffs cost ¥10 billion, exactly offsetting it. A weaker yen added a further ¥10 billion. And then adjustment items — the things excluded from adjusted profit — doubled from ¥20 billion to ¥40 billion: roughly ¥9 billion of acquisition-related costs and intangible amortisation, and roughly ¥9 billion from terminating an exclusive distribution agreement in the interventional business with Orchestra BioMed.[^6]

So: the operating business met or beat plan; tariffs were absorbed; and the guidance cut was almost entirely self-inflicted portfolio surgery. Management said so plainly rather than blaming the macro environment, and when an analyst pressed on whether more surprises were coming, Hagimoto declined to promise there would not be — noting ongoing structural reforms and pending litigation and saying it was "hard to give an absolutely setting stone guidance in terms of amounts."[^6]

That is a defensible way to handle a miss: attribute it correctly, refuse to over-promise. It is also, from the outside, a two-year pattern of large "one-time" charges that are no longer obviously one-time. The year to March 2025 carried ¥24.2 billion of temporary losses, comprising ¥17.9 billion of impairments and ¥7.5 billion of restructuring costs.¹ The year to March 2026 carried ¥18.8 billion, including ¥5.5 billion of litigation-related expense on disputes still under way, ¥4.5 billion of impairment plus ¥3.6 billion of related costs, and ¥3.9 billion of acquisition costs.¹

Two consecutive years of roughly ¥20 billion in charges excluded from the headline profit metric is precisely the kind of thing a short-seller builds a slide about. Management's counter, offered in February 2026, was that these were deliberate: costs pulled forward so that the final year of the plan could "end in a clean manner," including overseas workforce optimisation expected to save about ¥3 billion annually thereafter.¹⁴ Investors will find out whether that is true when the current year's adjustment line is disclosed. The specific, checkable prediction management has made is that adjusted and reported operating profit should converge. Guidance issued in August 2026 implies exactly that: adjusted operating profit of ¥274.5 billion against reported operating profit of ¥257.5 billion, a gap of ¥17 billion, most of which is acquisition-related amortisation that Terumo now has permanently.²¹

On incentives, Terumo's structure is conventional for Japan and modest by global medtech standards. Executive bonuses are driven 80% by company-wide financial performance for the chief executive and functional directors, with the financial indicators being consolidated revenue, operating profit, ROIC and ROE, and an achievement coefficient that varies between 0% and 150%.²⁶ The remaining 20% covers individually set non-financial "Future Corporate Value Targets" derived from the plan's ESG goals.²⁶ Restricted stock carries a transfer restriction of 30 years or until departure, with a clawback for misconduct — genuinely long-dated alignment.²⁶

The absolute numbers are small by international comparison: for the year to March 2025, seven executive directors received ¥505 million in aggregate — ¥236 million base, ¥144 million bonuses, ¥124 million restricted stock — and individual director remuneration is not disclosed.²⁶ Ten directors, five of them outside.²⁶ Whether modest pay and low direct ownership reduce alignment or reduce the temptation toward empire-building is a matter of philosophy. What it does mean is that the incentive to swing for a transformational acquisition is not financial. Samejima appears to have bought OrganOx because he believed in it.

Belief is a fine thing. It is also uninsured against the exposures the business actually carries.

↑ Back to Top

X. Currency, China, and the Risk Radar

Consider two ways to describe the same three months.

Terumo's revenue in the quarter ended June 30, 2026 grew 19.9% year-on-year to ¥311.8 billion, a record, with net profit up 68.3%.²¹ The company raised full-year profit guidance, and the shares rose 8.5% on the day.²¹³

Alternatively: Terumo's revenue grew 9.4% excluding currency, roughly half the reported rate. Its operating profit growth of 60.1% included ¥20.1 billion of one-off litigation settlement proceeds and a refund of previously paid US tariffs. And its China revenue — up 21.9% as reported — grew 3.4% in local terms.²¹

Both descriptions are accurate. The gap between them is the single most important thing to understand about reading this company's results.

Currency is not a footnote

Roughly 80% of Terumo's revenue is earned outside Japan — ¥909.3 billion of ¥1,131.9 billion in the year to March 2026, with the Americas at 39% of the total, Europe at 21%, other Asia at 12% and China at 8%.¹ Costs are considerably more Japan-weighted, because a substantial portion of manufacturing sits in Japan.

That asymmetry means a weakening yen inflates revenue, margin and profit simultaneously. Over the plan period the effect was worth five full percentage points of compound revenue growth — the difference between the 12% headline and the 7% constant-currency figure.⁹ Terumo's actual realised rate in the year to March 2026 was ¥151 to the dollar and ¥175 to the euro, against the ¥107 and ¥128 assumed when the plan was written.¹⁴ Guidance for the current year assumes ¥155 and ¥180.¹

The exposure works in both directions, and management has been explicit that the balance-sheet translation effects can hurt: on both the November 2025 and February 2026 calls, executives flagged negative currency impact on segment margins on a "stock" basis even while flow effects helped revenue.[^6]¹⁴ A sustained yen recovery would compress reported growth sharply without any change in underlying demand. Investors who anchor on reported yen growth rates are, in effect, running an unhedged currency position inside their operating thesis.

China: small, growing, and structurally squeezed

China is 8% of Terumo's revenue — meaningful but not dominant.¹ The risk is not the current exposure. It is the pricing mechanism.

Beijing's 带量采购 volume-based procurement runs national tenders in which the state consolidates demand and negotiates as a single buyer. The results in device categories have been severe. In the coronary stent tender, average selling prices for the ten selected products fell about 93%, from roughly RMB 10,242 to RMB 676, with imported stents cut by around 95% — steeper than domestic products, because they started higher.²⁷ Joint replacements were cut roughly 82%.²⁷

That is the mechanism to hold in mind: a category can lose nine-tenths of its price in a single tender round, and foreign products take the deepest cut.

Terumo's China experience has so far been more nuanced than pure destruction, and the nuance matters. Management has repeatedly described VBP as expanding market access — lower prices generating volume growth and, in the case of Terumo Neuro, "expanded market access resulting from VBP."¹⁴ In the year to March 2025 the interventional business rebounded from earlier price declines through volume.¹⁵ Management quantified the VBP drag at roughly ¥4 billion in one year, expected to be similar in the following year, and assumed continued rollout to additional provinces.¹⁵

So the empirical record shows volume offsetting price — for now. Three cautions apply. First, that offset is arithmetically finite: a 90% price cut requires a tenfold volume increase to stand still. Second, Terumo has already recognised an impairment for "deterioration of profitability" in its Chinese interventional business, tested at a 10.7% discount rate — the accounts contain a formal management judgement that at least part of the Chinese business is worth less than it was.¹ Third, the June 2026 quarter's 3.4% constant-currency China growth, against 12.2% in the Americas, is the weakest regional number in the group.²¹

The honest reading: China is not currently breaking Terumo, and management's channel-expansion argument has evidence behind it. But it is the region where reported growth most overstates underlying performance, and where a single tender covering access devices or neurovascular products could change the picture in a quarter.

Tariffs, integration, and what does not matter

US tariffs became a live line item during the year. Terumo initially sized the maximum exposure at roughly ¥17 billion, declined to include it in guidance given the fluidity, and then absorbed it: ¥2.5 billion of impact in one quarter offset by ¥4 billion of pricing, and ¥4.2 billion of tariff cost in another quarter against ¥3.5 billion of pricing benefit.¹⁴¹⁵ The full-year drag settled at roughly ¥10 billion, fully offset by pricing.[^6] The first quarter of the current year then received a refund of previously paid tariffs, which was one of the two reasons for the August guidance raise.²¹

The demonstrated ability to pass through cost is genuine evidence of pricing power — and worth contrasting with the peer set: on the May 2025 call, a Macquarie analyst noted that Terumo's guided tariff impact was proportionally larger than Olympus's, and that most drug companies had said they could not pass costs on.¹⁵ Terumo said it would try, and it did. That is a real, evidenced competitive attribute.

Integration risk is the exposure that deserves the most weight, because it is the one Terumo chose. Two businesses acquired within a month of each other, both overseas, both outside the company's operating competence — transplant clinical workflow in one case, European biologics manufacturing in the other — with a combined ¥257.7 billion of consideration and ¥148.7 billion of goodwill on the balance sheet.¹ Goodwill of that scale is not amortised under IFRS; it is tested annually. If OrganOx's growth trajectory disappoints, the adjustment arrives as a single large impairment rather than a gradual drag.

Conversely, some risks that dominate other sectors barely apply here. AI-driven disruption of a hydrophilic-coated guidewire is not a coherent threat. Cybersecurity matters operationally but is not existential for a consumables manufacturer. Demand is demographically underwritten by ageing populations. The slow, evidence-bound, trust-based nature of this industry cuts both ways: it protects Terumo from disruption, and it is exactly why the company's own expansion into new categories takes years.

↑ Back to Top

XI. Bull Case vs. Bear Case

Set the two arguments against each other properly, because both are strong and neither is obviously right.

The bull case

Terumo has delivered six consecutive years of record revenue and profit, and the underlying operating record is better than the headline suggests once one accepts that currency helped: 7% constant-currency compound revenue growth over five years, with adjusted margin recovering from a post-pandemic, inflation-hit trough to 19.4%.¹⁹

Its core advantage is real, evidenced and unusual. Terumo dominates a category — vascular access — that competitors treat as an accessory business, and it does so through accumulated process capability and physician habit rather than patents that expire. The radial access practice it helped establish reached 79% penetration in coronary work on the company's own tracking, and management's claim that volume rather than price drives access growth is corroborated by segment disclosure.¹⁴⁵ Demonstrated tariff pass-through is direct evidence of pricing power.

Three-pillar diversification is genuine rather than cosmetic: when Medical Care Solutions was crushed by inflation, blood technology and cardiovascular carried the group; when Rika consumables softened, interventional pricing offset it. The pillars do not fail together.

The M&A record contains one clear compounder in Terumo Neuro, one strategically correct if expensive platform in Terumo BCT, and one small failure killed cleanly in Quirem. Recent deals add real optionality: contract manufacturing exposure to the biologics and injectable-therapy wave, cell and gene therapy manufacturing infrastructure, and organ preservation.

And the overseas mix — 80% of revenue — insulates Terumo from a shrinking, price-controlled domestic healthcare budget in a country whose population is contracting. Japanese revenue grew 2.5% last year; the Americas grew 13.6% in local currency.¹ Terumo is a Japanese-listed company with a substantially non-Japanese business.

The bear case

Terumo does not lead where the money is. Structural heart and US drug-eluting stents belong to Edwards, Abbott, Boston Scientific and Medtronic — larger companies with deeper R&D budgets in categories with better economics than access devices. Management's answer is to buy its way into therapeutics, which is expensive and, on the recent record, error-prone: two consecutive years of programme terminations and impairments concentrated in exactly the divisions attempting that move.¹

The two largest deals in company history share a profile — full price for category entry, payback measured in a decade — and only one has enough history to grade. That one, CaridianBCT, still runs a segment margin below its own target fifteen years on.¹⁵

Reported growth is currency-flattered to a degree that would surprise anyone reading only headlines, and the gap has been widening: 19.9% reported versus 9.4% constant currency in the most recent quarter.²¹

The newest bets are unproven and simultaneous. The German plant is loss-making with no announced customers and no expected profit contribution within the current plan period. Organ technology has two quarters of ownership, is exposed to donor supply the company does not control, and sits on ¥138.2 billion of goodwill.¹[^6]

And a skeptical investor would press hard on three governance points. The 50% total payout target produced a 33% payout while the company borrowed to buy assets. Two consecutive years of roughly ¥20 billion in "temporary" charges raise the question of when temporary becomes recurring. And the GS26 victory slide reports achievement on an adjusted basis excluding the very acquisitions that define the company's next chapter, while reported ROE has never touched the 10% the plan promised.¹⁹

Myth vs. reality

Three consensus statements about Terumo deserve testing.

Myth: Terumo is a Japanese company. Reality: it is a Japanese-listed company with roughly 80% of revenue and the overwhelming majority of its growth outside Japan, its fastest-growing division headquartered in California, its newest segment in Oxford, and its largest single market the United States.¹ The Japanese exposure that matters most is not demand — it is the cost base and the reporting currency.

Myth: Terumo makes commodity consumables and therefore has commodity economics. Reality: the Cardiac and Vascular Company earned a 24% segment margin on products the industry classifies as accessories.¹ Physician tactile preference and manufacturing consistency do the work that patents do elsewhere.

Myth: the record results prove the strategy is working. Reality: the record results prove demand is strong and the yen is weak. What they do not yet prove is that ¥257.7 billion deployed into two unfamiliar categories will earn its cost of capital. That evidence does not exist yet, and no amount of revenue records substitutes for it.

The frameworks, applied

Through Porter's lens, the industry is genuinely attractive on three forces — entry barriers, supplier power, and substitution, which runs in Terumo's favour as catheter procedures displace open surgery — and unattractive on two. Buyer power is high and consolidating, with national tenders representing its most extreme form. Rivalry is intense among well-capitalised global peers.

Through Helmer's Seven Powers, Terumo holds two clearly and shares a third. Process power is its strongest and least replicable asset: decades of coating chemistry and precision manufacturing that no competitor can buy off a shelf. Switching costs are real but soft — physician habit rather than contractual lock-in, which means they erode if a rival builds a demonstrably better device. Scale economies exist but are shared with larger rivals, which is precisely the problem in implantables. Terumo has no meaningful network economies, no cornered resource of consequence, and its brand power is professional rather than consumer — genuinely valuable with cardiologists, worth nothing with patients.

That combination describes a company with a deep, narrow moat rather than a wide one. It defends its castle extremely well. Expanding the castle is where the risk lives.

↑ Back to Top

XII. Durable Lessons and What to Watch

Three lessons generalise beyond this company.

Narrow technical focus can outrun breadth. Terumo's most durable advantage came from doing one physically difficult thing — putting a slippery, consistent coating on a wire — better than anyone else, for forty years. It did not diversify its way to that advantage; it compounded it. The general principle is that in businesses where the customer cannot see the product working and must trust it absolutely, manufacturing consistency is a competitive weapon and narrowness is a feature. The corollary, visible in Terumo's own impairment history, is that the same company can be excellent at one hard thing and mediocre at adjacent hard things.

Bolt-on acquisition compounds differently from transformation. MicroVention was bought small, held for eighteen years, allowed to keep its identity and its people, and grew into a $710 million franchise.⁹ Quirem was bought small enough that failure cost almost nothing and was killed on schedule.²⁴²⁵ Both were correct uses of the format. The format's virtue is that it converts capital allocation from a series of bets into a portfolio, where individual failures are survivable and individual successes are allowed to run. Terumo's recent shift toward larger, category-defining transactions abandons that virtue in exchange for speed.

Stated capital allocation frameworks reveal priorities under stress. Terumo's three-stage priority — growth investment, then dividend floor, then buyback — sounds like a formality until a year arrives when growth investment consumes everything. That happened. The framework was honoured exactly as written and the shareholder return target was not met, which is what the framework always implied. Investors should read such frameworks as rankings rather than promises.

What to watch

Three metrics carry most of the information about whether the thesis is working. They are deliberately few, and none requires calculation beyond what the company discloses.

Constant-currency revenue growth by segment. Terumo discloses this in every quarterly release, and it is the only way to separate genuine demand from the yen. The specific comparison that matters is the Cardiac and Vascular Company's local-currency rate — the franchise where the moat supposedly lives — against the roughly 8% it has been running.¹¹⁴ Sustained deceleration below mid-single digits would suggest access pricing is finally being competed away.

Terumo Organ Technologies revenue and segment margin. Disclosed as a standalone reportable segment every quarter, this is the cleanest read on whether the largest acquisition in company history is compounding as underwritten. The trajectory to watch is whether quarterly revenue keeps building toward the ¥100 billion ten-year ambition and whether margin recovers toward the 21% seen before purchase-accounting effects, rather than settling at the roughly 15% recorded in the most recent quarter.¹²¹[^6]

China revenue growth in local currency, alongside management's tender commentary. The reported figure is noise; the constant-currency figure is signal, and the qualitative commentary about which categories are entering volume-based procurement rounds is the leading indicator. A tender covering access devices or neurovascular products would be the single event most capable of resetting the margin structure of the group's most profitable segment.¹²¹

Beyond those, two events would materially change the case in either direction. A signed European pharmaceutical contract for the Leverkusen site would convert an expensive option into a business. A sustained yen appreciation would strip several points from reported growth and reveal precisely how much of the last five years was operational.

↑ Back to Top

XIII. Epilogue

There is a certain kind of company that Western investors systematically overlook: profitable, unglamorous, listed on an exchange they do not follow, selling products the end customer never sees, in a currency that distorts the headline numbers in both directions. Terumo has been that company for most of its listed life — a Tokyo Stock Exchange Prime constituent trading at roughly 23 times earnings, quietly supplying the consumables of interventional medicine to more than 160 countries while almost no one outside Japan and the cath lab could name it.³

What makes this moment worth attention is that Terumo is no longer behaving like that company.

The organisation that spent a hundred years perfecting the manufacture of small, precise, repeatable objects has, within a single fiscal year, bought a German pharmaceutical factory with no customers and an Oxford spinout that keeps human livers alive. It has taken on debt to do it, seen its equity ratio fall meaningfully, and put ¥148.7 billion of goodwill onto a balance sheet that carried very little before.¹ It did all of this while declaring victory on a five-year plan whose profitability target was measured excluding exactly those transactions.

The question is not whether Terumo is a good business. The evidence that it is — a 24% margin on so-called commodity products, demonstrated tariff pass-through, decades of physician loyalty — is about as clear as this kind of evidence gets.

The question is which Terumo is making capital allocation decisions now. There is a version of this company that bought MicroVention for a modest sum in 2006 and let it compound for eighteen years, and killed Quirem without sentiment when the thesis broke. There is another version that paid fifteen times EBITDA for CaridianBCT in 2011 and spent the following decade and a half earning it back, with the segment margin target still unmet.

Both versions are real. Both are the same company. Hikaru Samejima personally worked on the first deal in that sequence and personally authorised the largest one, and he now has to prove that a chief executive whose formative experience was buying things knows when to stop.

The next two or three earnings cycles will answer it. Organ technology is disclosed as its own segment, so the scoreboard is public and quarterly. The German plant's first customer contract, or its continued absence, will be visible. And the successor plan to GS26 — which management has previewed only as an aspiration to reach "global top-tier" — will reveal whether Terumo intends to keep buying its way up the value chain or return to compounding what it already owns.⁹

For a company that began because Japanese doctors could not get a reliable thermometer, it is a long way from the ward. Whether it is the right way is still, honestly, an open question.

Terumo Corporation

Table of Contents

Terumo Corporation: From Fever Thermometers to the Operating Room

I. Introduction & Episode Roadmap

II. Origins: A Thermometer Company Born of Wartime Necessity (1921–1970s)

III. Building Three Pillars Through M&A (1980s–2011)

IV. The Core Engine: Cardiac and Vascular — Industry Structure and How Terumo Wins

The industry structure, honestly described

What Terumo actually sells, and why it is more defensible than it looks

The imaging bet, explained simply

Where the evidence is thinner

V. Medical Care Solutions: The Ballast Business — and a New Growth Angle in CDMO

Deviceuticals, in plain language

Why Leverkusen, and what it has cost so far

VI. Blood and Cell Technologies: The Quiet Cash Compounder

The Rika story, and why it cuts both ways

The competitive set, and the adjacency

CaridianBCT, fifteen years on

VII. The Biggest Bet Yet: OrganOx and Entry into Organ Transplant Technology (2025)

The deal

Interrogating the price

What the first three quarters actually showed

VIII. The Capital Allocation Scorecard

Reading the scorecard critically

The shareholder return promise, and what actually happened

The M&A record, scored

IX. Leadership: The Samejima Era

The year Terumo guided down its own operating profit

X. Currency, China, and the Risk Radar

Currency is not a footnote

China: small, growing, and structurally squeezed

Tariffs, integration, and what does not matter

XI. Bull Case vs. Bear Case

The bull case

The bear case

Myth vs. reality

The frameworks, applied

XII. Durable Lessons and What to Watch

What to watch

XIII. Epilogue

References